Neuroscience Drug Pipeline Tracker
Krzysztof Potempa
Dreamster dedicated to the prevention and treatment of mental health disorders that affect at least 1 in 6 people worldwide!
Last updated: 12 June 2024
The aim of this article is to compile neuroscience drug development pipelines in one place to facilitate for example the exploration of efficacy of certain drugs across different neurological indications.
Please feel free to share other clinical trial pipeline trackers in the comments of this article or by private message so that I can expand this resource. By sharing information, we can speed up new therapies for people living with brain diseases.
Amyotrophic Lateral Sclerosis (ALS)
Alzheimer's Disease Clinical Trial Pipeline 2024
Alzheimer's Disease Clinical Trial Pipeline 2023
Alzheimer's Disease Clinical Trial Pipeline 2022
Agents in clinical trials for treatment of Alzheimer’s disease in 2021 (from clinicaltrials.gov as of the index date of January 5, 2021). The inner ring shows Phase 3 agents; themiddle ring comprises Phase 2 agents; the outer ring presents Phase 1 therapies; agents in green areas are biologics; agents in purple are disease-modifying small molecules; agents in orange areas are symptomatic agents addressing cognitive enhancement or behavioral and neuropsychiatric symptoms; the shape of the icon shows the population of the trial; the icon color shows the Common Alzheimer’s Disease ResearchOntology (CADRO)-based class of the agent (“Other” category includes CADROclasses that have three or fewer agents in trials). Agents underlined are new to the pipeline since 2020.
Epilepsy Pipeline Tracker
There are 79 Drugs associated with preclinical, Phase I, Phase II, and Phase III labels. A further 38 drugs do not have any specified label.
Friedreich's Ataxia Treatment Pipeline
Along the vertical axis lead candidates are grouped based on mechanism of action or approach to treatment, e.g., where or how each drug might work in the cell, technological approach, or problem being addressed. The horizontal axis indicates the stage of the research - where the candidate is in development.
Hearing Pipeline
Huntington's Disease Pipeline
Therapies In Pipeline | Huntington's Disease Society of America (hdsa.org)
Migraine
领英推荐
Multiple System Atrophy
Pain Therapeutics Pipeline
Top left: Pain pipeline by phase of development. Novel drugs that do not have an approval history, non-NME drugs that are reformulated or repurposed products, and each group split by opioid receptor activity. For combination drugs, only the novel active component is used to categorize as novel. If no novel compound is present in the combination drug, the Non-NME label is used. Bottom left: Radar plot by earliest (outer) to latest phase (center) and by type of pain. Biomedtracker indications for chronic pain, and chronic lower back pain are combined, postsurgical pain, and moderate to severe pain, acute and cancer pain were combined. Neuropathic pain includes general neuropathic pain along with Biomedtracker indications for neuropathies, neuralgia, sciatica, and fibromyalgia. Migraine and other headaches are grouped separately. Misc pain includes many phase I programs that are not specified as to the type of pain, and a few local anesthetics.
PD Clinical Trial Pipeline 2023
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline 2022
A schematic of all of the agents in active clinical trials for PD, registered on clinicaltrials.gov as of the 31st?January 2022.
Psychedelic Drug Development Tracker
Vision
Rare Diseases
Rett Syndrome and Fragile X Syndrome
CML @ Thermo Fisher Scientific | RBQM SME | Neuropsychologist
5 个月Thank you so much for sharing!
Pharmaceutical Physician - Independent Consulting for Neuroscience and CNS Therapeutics Development
1 年Thanks.
Associate Director Biopharm at UCL Business Ltd
2 年Thanks for sharing but someone forgot to put the ‘L’ in Alzheimer on the drug pipeline figure.
Futuristic neuroscientist grounded in electrical/biomedical engineering with biopsychosocial/educational entrepreneurial quests (both recruitable and innovating in stealth mode)
2 年Thanks for sharing!
Co-Founder & COO at Solvemed | Adj. Professor at IE University Madrid | Hon. Lecturer at University College London
2 年Thanks for sharing Krzysztof Potempa! We found this article very insightful here at Solvemed Group.